Sabto and transplant stuff Flashcards
PML is an absolute contraindication to organ donation? T/F
TRUE
(tissues and organs)
HEV is a contraindiaction to organ and tissue donation T/F
FALSE
Screen donors to establish monitoring in recipient
Influenza is a CI to organ donation
FALSE
-accept lung, if they died of flu, don’t use the lung, and if they died WITH flu, high risk but not a reject
Mandatory tests for a solid organ donor
HBV- surface and core
HCV
HIV
mandatory tests for a gamete donor
HBV- surface and core
HCV
HIV
HTLV
Syphilis
Mandatory tests for Stem cell donor
HIV
HBV- core and surface antibody
CV
Syph
HTLV
Absolute contra-indications to solid organ donation
TSE
Confirmed HHV-8 infection
Confirmed PML (JC virus)
MERS and SARS-1
Rabies
Yellow fever
Acute illness with MPox
VHF
When COVID-19 was the cause of death
Those which say “contra-indication but not Absolute”
Known Dengue virus infection
13.18.4.1 Is a contraindication to donation of Solid Organs for
Transplantation.
Known Chikungunya virus infection
13.19.5.1 Is a contraindication to donation of Solid Organs for
Transplantation
Donation may be considered 6 months after recovery from infection with
Chikungunya virus. same for dengue
Known Zika virus infection
13.20.6.1 Is a contraindication to donation of Solid Organs for
Transplantation except in exceptional circumstance.
13.20.6.2 Is a contraindication to tissue donation.
13.20.7 Donation may be considered 6 months after recovery from infection with
Zika virus.
Known West Nile virus infection
13.21.3.1 Is a contraindication to donation of Solid Organs for
Transplantation.
MMR
Acute disease is an absolute contraindication to donation of tissues
unless life preserving
Acute illness with MPOX
An organ donor has MPOX- can you accept
Theoretical risk of transmission if the donor was viraemic
with asymptomatic infection or contact with MPX in the previous 21 days.
Acute illness,-> absolute contraindication to donation of
tissues and solid organs for transplantation
Donation can be accepted following exposure to Mpox more than 21 days
before, with no signs or symptoms of Mpox
Donation can be accepted after complete recovery from Mpox at least 14 days previously
Donor has COVID- can they donate?
Thus far, transmission has only been described through transplantation of lungs
where was subsequently
shown to be strongly positive for SARS-CoV-2 RNA
where COVID-19 is felt to
contribute to the cause of death, are currently not being considered for deceased organ donation.
Where positive screening results are compatible with recent, resolving, or current infection in the upper
and/or lower respiratory tract, evidence thus far indicates that transmission of SARS-CoV-2 through the transplantation of (non-lung) organs leading to COVID-19 in the recipient is unlikely. Non-lung organs
from these donors will now be offered.
What percentage of renal transplant patients develop BK reactivation?
15%
Half will go on to develop BK nephropathy
Typically occurs in first 12 months
Presentation of BK disease in HSCT patients
Causes of haemorrhagic cystitis post transplant (HSCT and solid)
Cyclophosphomide- AKA acreolin associated. Usually occurs early, and within 72 hours of agent given
Infectious. MESNA is used to help prevent, but not always effective
BK
Adeno
?CMV
Monitoring of BK post renal transplant
Blood PCR monthly for 9 months, then three monthly until 2 years
- also do if deteriorating renal function, and at time of a biopdy if they are having one
Plasma BKPyV loads >4 log10 c/mL are associated with an increased rate of biopsy‐proven PyVAN, whereby plasma BKPyV loads peaking above 6 log10 c/mL are seen in cases with extensive PyVAN pathology
FIrst repeat sample, consider RIS, consider biopsy
Histological findings of BK nephrophathy
SV40 immunohistochemistry positive
Decoy cells in urine
Management options for BK nephropathy
RIS- calciunuerin inhibitors, and antiproliferative drugs
Reducs steroids
Additional strategies have been switching from tacrolimus to low‐ dose cyclosporine‐A, or switching from the calcineurin inhibitors to sirolimus, or switching from mycophenolic acid to low‐dose sirolimus, or from mycophenolic acid to leflunomide